一分钟看懂
这是一项关于小细胞肺癌的III 期研究，登记的药物或干预包括Tarlatamab，当前状态为招募中。登记地点显示中国北京、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tarlatamab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Chaoyang Hospital · 北京
- Beijing Cancer Hospital · 北京
- Shanghai Pulmonary Hospital · 上海
公开的入选条件
- * Participant has provided informed consent prior to initiation of any study specific activities/procedures.
- * Age ≥ 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
- * Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
- * Participants who progressed or recurred following 1 platinum-based regimen.
- * Measurable disease as defined per RECIST 1.1 within the 21-day screening period.
- * Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
- * Minimum life expectancy of 12 weeks.
- * Adequate organ function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07778316；登记信息更新于 2026-09-17。